Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients
This qualitative, cross-sectional study aimed to understand the barriers and facilitators related to the adherence and completion of the recombinant zoster vaccine (RZV) two-dose series in Canada, as perceived by healthcare providers (HCPs) and patients. Data collection occurred via 60-minute concep...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2317595 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689044833796096 |
|---|---|
| author | Sydney George Jessica Regan Amnah Awan Meaghan O’Connor April Foster Kimberly Raymond Iris Gorfinkel Shelly A. McNeil |
| author_facet | Sydney George Jessica Regan Amnah Awan Meaghan O’Connor April Foster Kimberly Raymond Iris Gorfinkel Shelly A. McNeil |
| author_sort | Sydney George |
| collection | DOAJ |
| description | This qualitative, cross-sectional study aimed to understand the barriers and facilitators related to the adherence and completion of the recombinant zoster vaccine (RZV) two-dose series in Canada, as perceived by healthcare providers (HCPs) and patients. Data collection occurred via 60-minute concept elicitation interviews with 12 HCPs (4 physicians, 2 nurse practitioners, 6 pharmacists) who had prescribed and/or administered RZV in Canada, and 21 patients aged ≥50 years who had received ≥1 dose of RZV. Patients were categorized as adherent (received both doses within the recommended 2-to-6-month timeframe; n = 11) or non-adherent (received only one dose or second dose outside the recommended timeframe; n = 10). Interview transcripts were coded and analyzed using a two-part thematic analysis approach. HCP-identified barriers to RZV adherence included high out-of-pocket cost, inconsistent/lack of health plan coverage, inconvenient processes for accessing RZV, and patient forgetfulness. HCP-identified facilitators included desire for shingles protection, HCP encouragement, and reminders. Barriers to RZV adherence identified by patients included lack of HCP knowledge/experience with RZV, receiving unreliable/confusing information, having unpleasant/severe side effects following the first dose, high out-of-pocket cost, lack of insurance coverage, and forgetfulness. Patient-identified facilitators included self-motivation, financial support, convenient processes for obtaining RZV, and reminders. In conclusion, many factors can influence RZV series completion and adherence among adults in Canada, including cost, insurance coverage, HCP knowledge and encouragement, and reminders. Awareness of these factors may inform HCPs in helping patients overcome barriers and identify opportunities for future consideration, facilitating protection against herpes zoster. |
| format | Article |
| id | doaj-art-882ef0cde00f4d719215addca2b4946b |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-882ef0cde00f4d719215addca2b4946b2025-08-20T03:21:46ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2317595Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patientsSydney George0Jessica Regan1Amnah Awan2Meaghan O’Connor3April Foster4Kimberly Raymond5Iris Gorfinkel6Shelly A. McNeil7GSK, Mississauga, ON, CanadaGSK, Mississauga, ON, CanadaGSK, Mississauga, ON, CanadaQualityMetric Inc., Johnston, RI, USAQualityMetric Inc., Johnston, RI, USAQualityMetric Inc., Johnston, RI, USAPrimeHealth Clinical Research, Toronto, ON, CanadaCanadian Center for Vaccinology, IWK Health and Nova Scotia Health, Dalhousie University, Halifax, NS, CanadaThis qualitative, cross-sectional study aimed to understand the barriers and facilitators related to the adherence and completion of the recombinant zoster vaccine (RZV) two-dose series in Canada, as perceived by healthcare providers (HCPs) and patients. Data collection occurred via 60-minute concept elicitation interviews with 12 HCPs (4 physicians, 2 nurse practitioners, 6 pharmacists) who had prescribed and/or administered RZV in Canada, and 21 patients aged ≥50 years who had received ≥1 dose of RZV. Patients were categorized as adherent (received both doses within the recommended 2-to-6-month timeframe; n = 11) or non-adherent (received only one dose or second dose outside the recommended timeframe; n = 10). Interview transcripts were coded and analyzed using a two-part thematic analysis approach. HCP-identified barriers to RZV adherence included high out-of-pocket cost, inconsistent/lack of health plan coverage, inconvenient processes for accessing RZV, and patient forgetfulness. HCP-identified facilitators included desire for shingles protection, HCP encouragement, and reminders. Barriers to RZV adherence identified by patients included lack of HCP knowledge/experience with RZV, receiving unreliable/confusing information, having unpleasant/severe side effects following the first dose, high out-of-pocket cost, lack of insurance coverage, and forgetfulness. Patient-identified facilitators included self-motivation, financial support, convenient processes for obtaining RZV, and reminders. In conclusion, many factors can influence RZV series completion and adherence among adults in Canada, including cost, insurance coverage, HCP knowledge and encouragement, and reminders. Awareness of these factors may inform HCPs in helping patients overcome barriers and identify opportunities for future consideration, facilitating protection against herpes zoster.https://www.tandfonline.com/doi/10.1080/21645515.2024.2317595Canadaherpes zostervaccinesvaricella zoster virus |
| spellingShingle | Sydney George Jessica Regan Amnah Awan Meaghan O’Connor April Foster Kimberly Raymond Iris Gorfinkel Shelly A. McNeil Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients Human Vaccines & Immunotherapeutics Canada herpes zoster vaccines varicella zoster virus |
| title | Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients |
| title_full | Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients |
| title_fullStr | Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients |
| title_full_unstemmed | Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients |
| title_short | Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients |
| title_sort | attitudes barriers and facilitators to adherent completion of the recombinant zoster vaccine regimen in canada qualitative interviews with healthcare providers and patients |
| topic | Canada herpes zoster vaccines varicella zoster virus |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2317595 |
| work_keys_str_mv | AT sydneygeorge attitudesbarriersandfacilitatorstoadherentcompletionoftherecombinantzostervaccineregimenincanadaqualitativeinterviewswithhealthcareprovidersandpatients AT jessicaregan attitudesbarriersandfacilitatorstoadherentcompletionoftherecombinantzostervaccineregimenincanadaqualitativeinterviewswithhealthcareprovidersandpatients AT amnahawan attitudesbarriersandfacilitatorstoadherentcompletionoftherecombinantzostervaccineregimenincanadaqualitativeinterviewswithhealthcareprovidersandpatients AT meaghanoconnor attitudesbarriersandfacilitatorstoadherentcompletionoftherecombinantzostervaccineregimenincanadaqualitativeinterviewswithhealthcareprovidersandpatients AT aprilfoster attitudesbarriersandfacilitatorstoadherentcompletionoftherecombinantzostervaccineregimenincanadaqualitativeinterviewswithhealthcareprovidersandpatients AT kimberlyraymond attitudesbarriersandfacilitatorstoadherentcompletionoftherecombinantzostervaccineregimenincanadaqualitativeinterviewswithhealthcareprovidersandpatients AT irisgorfinkel attitudesbarriersandfacilitatorstoadherentcompletionoftherecombinantzostervaccineregimenincanadaqualitativeinterviewswithhealthcareprovidersandpatients AT shellyamcneil attitudesbarriersandfacilitatorstoadherentcompletionoftherecombinantzostervaccineregimenincanadaqualitativeinterviewswithhealthcareprovidersandpatients |